FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

MANHARD KIMBERLY
2. Issuer Name and Ticker or Trading Symbol

HERON THERAPEUTICS, INC. /DE/ [ HRTX ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Executive VP, Drug Development
(Last)          (First)          (Middle)

4242 CAMPUS POINT COURT, SUITE 200
3. Date of Earliest Transaction (MM/DD/YYYY)

5/1/2020
(Street)

SAN DIEGO, CA 92121
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 4/30/2020  J(1)  V 1158 A$12.121 1158 D  
Common Stock 5/1/2020  S(2)  1158 D$13.9687 (3)0 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares

Explanation of Responses:
(1) Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2020.
(2) The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of June 13, 2019.
(3) The range of sales prices received was $13.91 to $14.06. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
MANHARD KIMBERLY
4242 CAMPUS POINT COURT
SUITE 200
SAN DIEGO, CA 92121
X
Executive VP, Drug Development

Signatures
/s/ Lisa R. Peraza Attorney-in-fact for Kimberly Manhard5/1/2020
**Signature of Reporting PersonDate

Heron Therapeautics (NASDAQ:HRTX)
Historical Stock Chart
From Jun 2020 to Jul 2020 Click Here for more Heron Therapeautics Charts.
Heron Therapeautics (NASDAQ:HRTX)
Historical Stock Chart
From Jul 2019 to Jul 2020 Click Here for more Heron Therapeautics Charts.